Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

The failure of Pfizer Inc.’s obesity pill, its highest profile experimental drug, raises the odds that the drugmaker will ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

Pfizer Inc. dejará de desarrollar una píldora contra la obesidad que ha sido seguida de cerca por los inversores, un duro ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.